Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Invested Capital (2016 - 2025)

Historic Invested Capital for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $339.4 million.

  • Collegium Pharmaceutical's Invested Capital rose 1356.11% to $339.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.4 million, marking a year-over-year increase of 1356.11%. This contributed to the annual value of $293.4 million for FY2024, which is 2253.09% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Invested Capital is $339.4 million, which was up 1356.11% from $296.8 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Invested Capital ranged from a high of $846.1 million in Q1 2022 and a low of $293.4 million during Q4 2024
  • For the 5-year period, Collegium Pharmaceutical's Invested Capital averaged around $484.4 million, with its median value being $394.8 million (2021).
  • In the last 5 years, Collegium Pharmaceutical's Invested Capital surged by 16436.98% in 2022 and then crashed by 5456.49% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Invested Capital (Quarter) stood at $346.7 million in 2021, then soared by 122.06% to $769.8 million in 2022, then plummeted by 50.8% to $378.8 million in 2023, then dropped by 22.53% to $293.4 million in 2024, then grew by 15.67% to $339.4 million in 2025.
  • Its Invested Capital was $339.4 million in Q3 2025, compared to $296.8 million in Q2 2025 and $299.0 million in Q1 2025.